Immunogenicity after switching from reference infliximab to biosimilar in children with Crohn's disease

被引：0
|
作者：
Sieczkowska, J. [1 ]
Jarzebicka, D. [1 ]
Oracz, G. [1 ]
Meglicka, M. [1 ]
Dadalski, M. [1 ]
Kierkus, J. [1 ]
机构：
[1] Childrens Mem Hlth Inst, Dept Gastroenterol Hepatol Feeding Disorders & Pa, Warsaw, Poland
来源：
JOURNAL OF CROHNS & COLITIS | 2016年 / 10卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P617
引用
收藏
页码：S413 / S414
页数：2
相关论文
共 50 条
  • [21] Bioavailability, safety and immunogenicity of biosimilar infliximab (BOW015) compared to reference infliximab
    Lambert, John
    Wyand, Michael
    Lassen, Cheryl
    Shneyer, Lucy
    Thomson, Elizabeth
    Knight, Alastair
    Willers, Joerg
    Kay, Jonathan
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2016, 54 (04) : 315 - 322
  • [22] Infliximab dependency in children with Crohn's disease
    Duricova, D.
    Pedersen, N.
    Lenicek, M.
    Hradsky, O.
    Bronsky, J.
    Adamcova, M.
    Elkjaer, M.
    Andersen, P. S.
    Vitek, L.
    Larsen, K.
    Lukas, M.
    Nevoral, J.
    Wewer, V.
    Munkholm, P.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2009, 29 (07) : 792 - 799
  • [23] SWITCHING FROM ORIGINATOR INFLIXIMAB TO BIOSIMILAR INFLIXIMAB: EFFICACY AND SAFETY IN A COHORT OF PATIENTS WITH ESTABLISHED BEHCET'S DISEASE
    Venerito, V.
    Lopalco, G.
    Cantarini, L.
    Fabiani, C.
    Nivuori, M.
    Cacciapaglia, F.
    Galeazzi, M.
    Lapadula, G.
    Iannone, F.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 1494 - 1495
  • [24] SWITCHING FROM INFLIXIMAB ORIGINATOR TO A BIOSIMILAR DOES NOT AFFECT PHARMACOKINETICS, IMMUNOGENICITY AND EFFICACY IN PEDIATRIC PATIENTS WITH INFLAMMATORY BOWEL DISEASE
    van Hoeve, Karen
    Dreesen, Erwin
    Hoffman, Ilse
    Ferrante, Marc
    Ann, Gils
    Vermeire, Severine
    GASTROENTEROLOGY, 2019, 156 (06) : S199 - S199
  • [25] Switching from infliximab originator to a biosimilar does not affect efficacy, pharmacokinetics and immunogenicity in paediatric patients with inflammatory bowel disease
    van Hoeve, K.
    Dreesen, E.
    Hoffman, I.
    Ferrante, M.
    Gils, A.
    Vermeire, S.
    JOURNAL OF CROHNS & COLITIS, 2019, 13 : S313 - S314
  • [26] Comparison of Techniques for Monitoring Infliximab Bioavailability and Immunogenicity in Crohn's Disease
    Steenholdt, Casper
    Svenson, Morten
    Ainsworth, Mark A.
    Thomsen, Ole.
    Brynskov, Jorn
    Bendtzen, Klaus
    GASTROENTEROLOGY, 2012, 142 (05) : S781 - S781
  • [27] Similar But Not Identical: Plaque Psoriasis Exacerbation in a Patient With Crohn's Disease After Switching From CT-P13 to SB2 Infliximab Biosimilar
    Pagnini, Cristiano
    Di Paolo, Maria Carla
    De Angelis, Giulia
    Torcolacci, Federica
    Milano, Michele
    Trinca, Daniela
    Porciello, Roberto
    Graziani, Maria Giovanna
    INFLAMMATORY BOWEL DISEASES, 2020, 26 (08) : E83 - E84
  • [28] Assessment of safety and efficacy of biosimilar infliximab in children with Crohn disease: a preliminary report.
    Sieczkowska, J.
    Banaszkiewicz, A.
    Plocek, A.
    Jarzebicka, D.
    Gawronska, A.
    Toporowska-Kowalska, E.
    Kierkus, J.
    JOURNAL OF CROHNS & COLITIS, 2015, 9 : S295 - S295
  • [29] Pharmacokinetics and immunogenicity of Infliximab biosimilar in inflammatory bowel disease patients
    Guardiola, J.
    Rodriguez Alonso, L.
    Padulles, N.
    Santacana, E.
    Serra, K.
    Padulles, A.
    Ruiz-Cerulla, A.
    Gilabert, P.
    Arajol, C.
    Ibanez-Sanz, G.
    Camps, B.
    Colom, H.
    Bas, J.
    Morandeira, F.
    Sanchez, E.
    Orobitg, J.
    Rodriguez Moranta, F.
    JOURNAL OF CROHNS & COLITIS, 2019, 13 : S441 - S441
  • [30] Long-term effectiveness, safety and immunogenicity of the biosimilar SB2 in inflammatory bowel disease patients after switching from originator infliximab
    Fischer, Sarah
    Cohnen, Sarah
    Klenske, Entcho
    Schmitt, Heike
    Vitali, Francesco
    Hirschmann, Simon
    Ramming, Andreas
    Zundler, Sebastian
    Rath, Timo
    Krebs, Sabine
    Dorje, Frank
    Uter, Wolfgang
    Nagore, Daniel
    Meyer, Sebastian
    Neurath, Markus F.
    Atreya, Raja
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2021, 14
12345